newsfilter
← Latest News
GlobeNewswire·

Lipella Pharmaceuticals Doses First Two Patients in Phase 2a Oral Lichen Planus Clinical Trial

PITTSBURGH, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) ("Lipella," "our," "us," "we" or the "Company"), a clinical-stage biotechnology company addressing serious diseases with